Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium

Oncogene

Volumn 30, Issue 6, 2011, Pages 724-736

  Suo, J ^a   Snider, S J ^a   Mills, G B ^b   Creighton, C J ^a   Chen, A C ^a   Schiff, R ^a   Lloyd, R E ^a   Chang, E C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

eIF3; proteasomes; translation; tumor suppressor; ubiquitin

Indexed keywords

INITIATION FACTOR; INITIATION FACTOR 3; MESSENGER RNA; ONCOPROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN FBW7; PROTEIN INT6; PROTEIN SUBUNIT; STEROID RECEPTOR COACTIVATOR 3; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACINI; ARTICLE; BREAST EPITHELIUM; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE LOSS; GENE SILENCING; HELA CELL; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALIGNANT TRANSFORMATION; MORPHOGENESIS; POLYSOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; TRANSLATION INITIATION; UBIQUITINATION;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-3; F-BOX PROTEINS; GENE SILENCING; HUMANS; MAMMARY GLANDS, HUMAN; NUCLEAR RECEPTOR COACTIVATOR 3; POLYRIBOSOMES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; RIBOSOMES; UBIQUITIN-PROTEIN LIGASES;

EUKARYOTA; SCHIZOSACCHAROMYCETACEAE;

EID: 79951508532     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.445     Document Type: Article

References (40)

1. Akiyoshi Y, Clayton J, Phan L, Yamamoto M, Hinnebusch AG, Watanabe Y et al. (2001). Fission yeast homolog of murine Int-6 protein, encoded by mouse mammary tumor virus integration site, is associated with the conserved core subunits of eukaryotic translation initiation factor 3. J Biol Chem 276: 10056-10062.
2. Aravind L, Ponting CP. (1998). Homologues of 26S proteasome subunits are regulators of transcription and translation. Protein Sci 7: 1250-1254. (Pubitemid 28237059)
3. Asano K, Merrick WC, Hershey JW. (1997). The translational initiation factor eIF3-p48 subunit is encoded by int6, a site of frequent integration by the mouse mammary tumor virus genome. J Biol Chem 272: 23477-23480. (Pubitemid 27410912)
4. Bandyopadhyay A, Matsumoto T, Maitra U. (2000). Fission yeast Int6 is not essential for global translation initiation, but deletion of int6+ causes hypersensitivity to caffeine and affects spore formation. Mol Biol Cell 11: 4005-4018.
5. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H et al. (2007). A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28: 501-512. (Pubitemid 350030573)
6. Byrd MP, Zamora M, Lloyd RE. (2005). Translation of eIF4GI proceeds from multiple mRNAs containing a novel cap-dependent IRES that is active during poliovirus infection. J Biol Chem 280: 18610-18622.
7. Crane R, Craig R, Murray R, Dunand-Sauthier I, Humphrey T, Norbury C. (2000). A fission yeast homolog of Int-6, the mammalian oncoprotein and eIF3 subunit, induces drug resistance when overexpressed. Mol Biol Cell 11: 3993-4003.
8. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. (1996). MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148: 313-319.
9. Debnath J, Muthuswamy SK, Brugge JS. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268. (Pubitemid 36677560)
10. Diella F, Levi G, Callahan R. (1997). Characterization of the INT6 mammary tumor gene product. DNA Cell Biol 16: 839-847. (Pubitemid 27332693)
11. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527. (Pubitemid 351655218)
12. Grzmil M, Rzymski T, Milani M, Harris AL, Capper RG, Saunders NJ et al. (2010). An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene 29: 4080-4089.
13. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS. (2005). Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 65: 11572-11580. (Pubitemid 41821716)
14. Hanna J, Leggett DS, Finley D. (2003). Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol 23: 9251-9261. (Pubitemid 37499812)
15. Hoareau Alves K, Bochard V, Rety S, Jalinot P. (2002). Association of the mammalian proto-oncoprotein Int-6 with the three protein complexes eIF3, COP9 signalosome and 26S proteasome. FEBS Lett 527: 15-21. (Pubitemid 35253831)
16. Hofmann K, Bucher P. (1998). The PCI domain: a common theme in three multiprotein complexes. Trends Biochem Sci 23: 204-205. (Pubitemid 28302615)
17. 0Malley BW. (2008). Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Molecular Cell 31: 835-849.
18. Lonard DM, O'Malley BW. (2008). SRC-3 transcription-coupled activation, degradation, and the ubiquitin clock: is there enough coactivator to go around in cells? Sci Signal 1: pe16.
19. Mack DL, Boulanger CA, Callahan R, Smith GH. (2007). Expression of truncated Int6/eIF3e in mammary alveolar epithelium leads to persistent hyperplasia and tumorigenesis. Breast Cancer Res 9: R42.
20. Marchetti A, Buttitta F, Miyazaki S, Gallahan D, Smith G, Callahan R. (1995). Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneopla-sia. J Virol 69: 1932-1938.
21. Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Callahan R. (2001). Reduced expression of INT-6/eIF3-p48 in human tumors. Int J Oncol 18: 175-179.
22. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK et al. (2006). Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66: 8266-8273. (Pubitemid 44299196)
23. Masutani M, Sonenberg N, Yokoyama S, Imataka H. (2007). Reconstitution reveals the functional core of mammalian eIF3. EMBO J 26: 3373-3383. (Pubitemid 47123530)
24. Mayeur GL, Hershey JW. (2002). Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e). FEBS Lett 514: 49-54. (Pubitemid 34251241)
25. Morris C, Jalinot P. (2005). Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation. Oncogene 24: 1203-1211. (Pubitemid 40313921)
26. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361. (Pubitemid 36395255)
27. Rasmussen SB, Kordon E, Callahan R, Smith GH. (2001). Evidence for the transforming activity of a truncated Int6 gene, in vitro. Oncogene 20: 5291-5301. (Pubitemid 32844061)
28. Rivera C, Lloyd RE. (2008). Modulation of enteroviral proteinase cleavage of poly(A)-binding protein (PABP) by PABP-associated factors. Virology 375: 59-72.
29. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J et al. (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401-406. (Pubitemid 36278858)
30. Sha Z, Brill LM, Cabrera R, Kleifeld O, Scheliga JS, Glickman MH et al. (2009). The eIF3 interactome reveals the translasome, a supercomplex linking protein synthesis and degradation machineries. Molecular Cell 36: 141-152.
31. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB et al. (2006). Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512-2521. (Pubitemid 44650915)
32. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA et al. (2009). Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 8: 1278-1294.
33. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536. (Pubitemid 34130608)
34. Woods A, Sherwin T, Sasse R, MacRae TH, Baines AJ, Gull K. (1989). Definition of individual components within the cytoskeleton of Trypanosoma brucei by a library of monoclonal antibodies. J Cell Sci 93: 491-500. (Pubitemid 19188092)
35. Wu RC, Feng Q, Lonard DM, O'Malley BW. (2007). SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129: 1125-1140. (Pubitemid 46891039)
36. Xu J, Wu RC, O'Malley BW. (2009). Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615-630.
37. Yen H-cS, Chang EC. (2000). Yin6, a fission yeast Int6 homolog, complexes with Moe1 and plays a role in chromosome segregation. Proc Natl Acad Sci USA 97: 14370-14375. (Pubitemid 32016582)
38. Yen HC, Chang EC. (2003). INT6-a link between the proteasome and tumorigenesis. Cell Cycle 2: 81-83.
39. Yen HC, Gordon C, Chang EC. (2003). Schizosaccharomyces pombe Int6 and Ras homologs regulate cell division and mitotic fidelity via the proteasome. Cell 112: 207-217. (Pubitemid 36144110)
40. Zhou C, Arslan F, Wee S, Krishnan S, Ivanov AR, Oliva A et al. (2005). PCI proteins eIF3e and eIF3 m define distinct translation initiation factor 3 complexes. BMC Biol 3: 14.